|
JP2000516743A
(ja)
*
|
1996-09-04 |
2000-12-12 |
インタートラスト テクノロージーズ コーポレイション |
信用インフラストラクチャストラクチャ支援システム、安全な電子交易、電子商取引、交易プロセス制御及び自動化のための方法及び技術、分散コンピューテーション及び権利管理
|
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
WO2001047922A2
(en)
|
1999-12-24 |
2001-07-05 |
Aventis Pharma Limited |
Azaindoles
|
|
US6638926B2
(en)
|
2000-09-15 |
2003-10-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
WO2002050073A1
(en)
*
|
2000-12-19 |
2002-06-27 |
Smithkline Beecham P.L.C. |
Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
|
|
KR100847169B1
(ko)
|
2000-12-21 |
2008-07-17 |
글락소 그룹 리미티드 |
혈관형성 조절제로서의 피리미딘아민
|
|
CA2432799C
(en)
*
|
2000-12-21 |
2008-08-19 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
WO2002079163A1
(en)
*
|
2001-03-30 |
2002-10-10 |
Smithkline Beecham Corporation |
Aminopyridine derivatives as estrogen receptor modulators
|
|
US6884804B2
(en)
|
2001-05-16 |
2005-04-26 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Src and other protein kinases
|
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
US20030176437A1
(en)
|
2001-08-31 |
2003-09-18 |
D.M. Watterson |
Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
|
|
WO2003030909A1
(en)
*
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
EP1432416B1
(en)
|
2001-09-26 |
2011-01-19 |
Pfizer Italia S.r.l. |
Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
|
|
TWI330183B
(enExample)
*
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
EP1474147B1
(en)
|
2001-12-07 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine-based compounds useful as gsk-3 inhibitors
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
EP1463730B1
(en)
|
2001-12-17 |
2006-04-19 |
SmithKline Beecham Corporation |
Pyrazolopyridazine derivatives
|
|
AU2002361846A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
|
US20030158195A1
(en)
*
|
2001-12-21 |
2003-08-21 |
Cywin Charles L. |
1,6 naphthyridines useful as inhibitors of SYK kinase
|
|
RS63204A
(sr)
*
|
2002-01-17 |
2006-10-27 |
Neurogen Corporation |
Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
MXPA04007697A
(es)
*
|
2002-02-06 |
2004-11-10 |
Vertex Pharma |
Compuestos de heteroarilo utiles como inhibidores de gsk-3.
|
|
EP1485100B1
(en)
*
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
ATE468336T1
(de)
|
2002-03-15 |
2010-06-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
AU2003225800A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Hayley Binch |
Azolylaminoazine as inhibitors of protein kinases
|
|
NZ536278A
(en)
*
|
2002-04-05 |
2007-05-31 |
Boehringer Ingelheim Pharma |
p38 kinase inhibitors for treating mucus hypersecretion associated with cystic fibrosis
|
|
ES2340475T3
(es)
|
2002-05-01 |
2010-06-04 |
Vertex Pharmaceuticals Incorporated |
Estructura cristalizada de proteina aurora-2 y sus bolsillos de union.
|
|
ATE493987T1
(de)
|
2002-05-22 |
2011-01-15 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
|
AU2003242252A1
(en)
*
|
2002-06-07 |
2003-12-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Bicyclic pyrimidine derivatives
|
|
JP4662764B2
(ja)
|
2002-06-14 |
2011-03-30 |
メルク セローノ ソシエテ アノニム |
アゾールメチリデンシアニド誘導体およびそれらのタンパク質キナーゼモジュレーターとしての使用
|
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
WO2004000318A2
(en)
|
2002-06-21 |
2003-12-31 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
|
DE60320560T2
(de)
*
|
2002-07-17 |
2008-12-11 |
Pfizer Italia S.R.L. |
Heterobicyclische pyrazolderivate als kinaseinhibitoren
|
|
CA2494367A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Scios Inc. |
Methods for improvement of lung function using tgf-.beta. inhibitors
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
SI1532145T1
(sl)
*
|
2002-08-02 |
2007-02-28 |
Vertex Pharma |
Pirazolni sestavki, koristni kot inhibitorji GSK-3
|
|
PT1532145E
(pt)
*
|
2002-08-02 |
2007-01-31 |
Vertex Pharma |
Composiçoes de pirazole úteis como inibidores de gsk-3
|
|
WO2004014865A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Merck Sharp & Dohme Limited |
Phenylpyridazine derivatives as ligands for gaba receptors
|
|
MXPA05001804A
(es)
|
2002-08-14 |
2005-05-27 |
Vertex Pharma |
Inhibidores de proteinas cinasas y usos de los mismos.
|
|
EP1537087B1
(fr)
*
|
2002-09-05 |
2012-11-28 |
Aventis Pharma S.A. |
Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
|
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
|
CA2498460A1
(en)
*
|
2002-09-10 |
2004-03-25 |
Scios Inc. |
Inhibitors of tfg.beta.
|
|
CA2506772A1
(en)
|
2002-11-01 |
2004-05-21 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of jak and other protein kinases
|
|
AU2003286895A1
(en)
|
2002-11-05 |
2004-06-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of jak and other protein kinases
|
|
SI2316831T1
(sl)
*
|
2002-11-21 |
2013-07-31 |
Novartis Ag |
2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
|
|
EP2316831B1
(en)
|
2002-11-21 |
2013-03-06 |
Novartis AG |
2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
|
|
US7759336B2
(en)
*
|
2002-12-10 |
2010-07-20 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compounds and medicinal use thereof
|
|
WO2004062662A1
(fr)
|
2002-12-12 |
2004-07-29 |
Aventis Pharma S.A. |
Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
|
|
FR2848554A1
(fr)
*
|
2002-12-12 |
2004-06-18 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
CA2509239A1
(en)
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
US7601718B2
(en)
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
|
JP2006521398A
(ja)
*
|
2003-03-28 |
2006-09-21 |
サイオス・インコーポレーテツド |
ＴＧＦβの二−環式ピリミジン阻害剤
|
|
US7763627B2
(en)
*
|
2003-04-09 |
2010-07-27 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
|
AU2004233827B2
(en)
*
|
2003-04-24 |
2009-05-28 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
WO2004096808A1
(en)
*
|
2003-04-28 |
2004-11-11 |
De Novo Pharmaceuticals Limited |
Triazine compounds and their use
|
|
EP1633351A1
(en)
*
|
2003-06-13 |
2006-03-15 |
Arena Pharmaceuticals, Inc. |
5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
|
|
EA200600069A1
(ru)
*
|
2003-06-20 |
2006-08-25 |
Коли Фармасьютикал Гмбх |
Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
|
|
TW200510373A
(en)
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
|
US7329664B2
(en)
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
NZ544756A
(en)
|
2003-07-22 |
2009-09-25 |
Astex Therapeutics Ltd |
3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
|
GB0317127D0
(en)
*
|
2003-07-22 |
2003-08-27 |
Astex Technology Ltd |
Pharmaceutical compounds
|
|
US8178671B2
(en)
|
2003-07-30 |
2012-05-15 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
|
|
AU2004263515A1
(en)
*
|
2003-08-05 |
2005-02-17 |
Vertex Pharmaceuticals Incorporated |
Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
|
|
US7226920B2
(en)
*
|
2003-08-06 |
2007-06-05 |
Vertex Pharmaceuticals Inc. |
Aminotriazole compounds useful as inhibitors of protein kinases
|
|
AU2004276341B2
(en)
*
|
2003-09-23 |
2011-04-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyrrole derivatives as protein kinase inhibitors
|
|
GB0323137D0
(en)
|
2003-10-03 |
2003-11-05 |
Chang Lisa C W |
2,4,6- Trisubstituted pyrimidines and their different uses
|
|
DE602004022187D1
(de)
|
2003-10-17 |
2009-09-03 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
|
|
US8455489B2
(en)
*
|
2003-11-10 |
2013-06-04 |
Exelixis, Inc. |
Substituted pyrimidine compositions and methods of use
|
|
EP1687004A4
(en)
*
|
2003-11-10 |
2009-04-08 |
Synta Pharmaceuticals Corp |
PYRIDINE COMPOUNDS
|
|
JP4772690B2
(ja)
|
2003-12-03 |
2011-09-14 |
ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド |
チューブリン阻害剤
|
|
CA2548172A1
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
|
AU2004297241A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Naphthyridine derivatives and their use as modulators of muscarinic receptors
|
|
JP2007514759A
(ja)
|
2003-12-19 |
2007-06-07 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
|
WO2005070891A2
(en)
|
2004-01-23 |
2005-08-04 |
Amgen Inc |
Compounds and methods of use
|
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
|
EP1745034A1
(en)
|
2004-02-11 |
2007-01-24 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
EP2543376A1
(en)
|
2004-04-08 |
2013-01-09 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
AU2005233632A1
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
US20050250829A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
|
HRP20080120T5
(hr)
*
|
2004-05-14 |
2012-07-31 |
Millennium@Pharmaceuticals |
Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
|
|
EP1598348A1
(en)
*
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Novel pyridazinone derivatives as inhibitors of CDK2
|
|
EP1604988A1
(en)
*
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
|
DE102004028862A1
(de)
*
|
2004-06-15 |
2005-12-29 |
Merck Patent Gmbh |
3-Aminoindazole
|
|
GB0415364D0
(en)
*
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
US20080261821A1
(en)
*
|
2004-07-21 |
2008-10-23 |
The Regents Of Te University Of California |
Mechanism-Based Crosslinkers
|
|
WO2006023931A2
(en)
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
KR101182978B1
(ko)
|
2004-08-19 |
2012-09-18 |
디에스엠 아이피 어셋츠 비.브이. |
고비등 공기 민감성 및/또는 온도 민감성의 유용한생성물의 혼합물 정류 방법
|
|
GB0419416D0
(en)
|
2004-09-01 |
2004-10-06 |
Inst Of Ex Botany Ascr |
4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
|
|
US7335672B2
(en)
|
2004-09-13 |
2008-02-26 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
CA2581454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
|
AR050948A1
(es)
|
2004-09-24 |
2006-12-06 |
Hoffmann La Roche |
Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
|
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
|
AU2005288858B2
(en)
|
2004-09-30 |
2011-04-21 |
Janssen R&D Ireland |
HCV inhibiting bi-cyclic pyrimidines
|
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
|
ATE479687T1
(de)
|
2004-10-15 |
2010-09-15 |
Takeda Pharmaceutical |
Kinaseinhibitoren
|
|
TW200621257A
(en)
*
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
|
CA2589102C
(en)
|
2004-11-02 |
2013-08-13 |
Northwestern University |
Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
|
|
MX2007005247A
(es)
|
2004-11-02 |
2008-03-13 |
Univ Northwestern |
Compuestos de piridazina, composiciones y metodos.
|
|
CA2587427A1
(en)
|
2004-11-17 |
2006-05-26 |
Miikana Therapeutics, Inc. |
Kinase inhibitors
|
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
|
ES2450566T3
(es)
|
2004-11-30 |
2014-03-25 |
Amgen Inc. |
Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
|
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
|
JP2008525422A
(ja)
*
|
2004-12-23 |
2008-07-17 |
ファイザー・プロダクツ・インク |
抗癌剤として有用な複素芳香族誘導体
|
|
WO2006074057A2
(en)
*
|
2004-12-30 |
2006-07-13 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
|
EP1856135B1
(en)
|
2005-01-19 |
2009-12-09 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
ES2336243T3
(es)
*
|
2005-01-26 |
2010-04-09 |
Schering Corporation |
Derivados de 3-(indazol-5-il)-(1,2,4)triazina y composiciones similares como inhibidores de proteina quinasa para el tratamiento del cancer.
|
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
|
CA2595834C
(en)
*
|
2005-02-04 |
2013-04-30 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
|
WO2006087530A1
(en)
|
2005-02-16 |
2006-08-24 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1863797A1
(en)
*
|
2005-03-23 |
2007-12-12 |
AstraZeneca AB |
2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
|
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
|
WO2006100310A1
(en)
|
2005-03-25 |
2006-09-28 |
Tibotec Pharmaceuticals Ltd |
Heterobicylic inhibitors of hcv
|
|
SI1869032T1
(sl)
*
|
2005-04-05 |
2008-12-31 |
Astrazeneca Ab |
Pirimidinski derivati za uporabo kot sredstva proti raku
|
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2006108489A1
(en)
|
2005-04-14 |
2006-10-19 |
F. Hoffmann-La Roche Ag |
Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
ES2545382T3
(es)
|
2005-04-28 |
2015-09-10 |
Mitsubishi Tanabe Pharma Corporation |
Derivado de cianopiridina y su uso como medicamento
|
|
EP1885369B1
(en)
|
2005-05-04 |
2015-09-23 |
Evotec AG |
Fused heterocyclic compounds, and compositions and uses thereof
|
|
WO2006117212A2
(en)
|
2005-05-04 |
2006-11-09 |
Develogen Aktiengesellschaft |
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
|
JP2008540391A
(ja)
*
|
2005-05-05 |
2008-11-20 |
アストラゼネカ アクチボラグ |
ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
|
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
|
EP1899323A2
(en)
*
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
|
EP1899332A1
(en)
|
2005-06-24 |
2008-03-19 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
|
|
ES2270715B1
(es)
|
2005-07-29 |
2008-04-01 |
Laboratorios Almirall S.A. |
Nuevos derivados de pirazina.
|
|
JP2009504771A
(ja)
*
|
2005-08-18 |
2009-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ピラジンキナーゼ阻害剤
|
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
|
EP1934219A1
(en)
|
2005-09-16 |
2008-06-25 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
UA96427C2
(en)
*
|
2005-09-30 |
2011-11-10 |
Мийкана Терапьютикс, Инк. |
Substituted pyrazole compounds
|
|
CA2622352C
(en)
*
|
2005-09-30 |
2014-05-27 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
|
ES2274712B1
(es)
|
2005-10-06 |
2008-03-01 |
Laboratorios Almirall S.A. |
Nuevos derivados imidazopiridina.
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
GB0520657D0
(en)
*
|
2005-10-11 |
2005-11-16 |
Ludwig Inst Cancer Res |
Pharmaceutical compounds
|
|
EP2377530A3
(en)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
EP2388259A1
(en)
|
2005-10-28 |
2011-11-23 |
AstraZeneca AB |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
|
EP1942879A1
(en)
|
2005-10-31 |
2008-07-16 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
DK1951684T3
(en)
|
2005-11-01 |
2016-10-24 |
Targegen Inc |
BIARYLMETAPYRIMIDIN kinase inhibitors
|
|
WO2007056163A2
(en)
*
|
2005-11-03 |
2007-05-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
SI1945632T1
(sl)
|
2005-11-08 |
2014-03-31 |
Vertex Pharmaceuticals Incorporated |
Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
|
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
|
US7572809B2
(en)
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
|
EP1966152A2
(en)
*
|
2005-12-20 |
2008-09-10 |
Takeda Pharmaceutical Company Limited |
Glucokinase activators
|
|
EP2537849A3
(en)
|
2006-01-17 |
2013-04-03 |
Vertex Pharmaceuticals, Inc. |
Azaindoles useful as inhibitors of janus kinases
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
KR20080103996A
(ko)
|
2006-02-16 |
2008-11-28 |
쉐링 코포레이션 |
Ｅｒｋ 억제제로서 피롤리딘 유도체
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
PE20080145A1
(es)
*
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
|
AU2007235237B2
(en)
*
|
2006-04-11 |
2011-08-18 |
Vertex Pharmaceuticals Incorporated |
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
|
|
EP2015750A2
(en)
|
2006-04-28 |
2009-01-21 |
Northwestern University |
Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
|
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
CL2007001873A1
(es)
|
2006-06-27 |
2008-01-04 |
Takeda Pharmaceutical |
Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
|
|
UY30444A1
(es)
*
|
2006-06-30 |
2008-01-31 |
Astrazeneca Ab |
Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
|
|
EP2043651A2
(en)
*
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
DK2049500T3
(da)
|
2006-07-06 |
2011-12-12 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
|
|
UA95641C2
(xx)
*
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
US8338435B2
(en)
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20080103165A1
(en)
*
|
2006-09-19 |
2008-05-01 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
BRPI0719883A2
(pt)
|
2006-10-09 |
2015-05-05 |
Takeda Pharmaceutical |
Inibidores de quinase
|
|
JP2010505961A
(ja)
*
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
ES2445791T3
(es)
|
2006-10-21 |
2014-03-05 |
Abbvie Deutschland Gmbh & Co Kg |
Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3
|
|
DE602007004750D1
(de)
*
|
2006-11-02 |
2010-03-25 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
|
|
WO2008077086A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
TW200840584A
(en)
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
|
WO2008077649A1
(en)
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infectons
|
|
WO2008077650A1
(en)
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
|
US8173647B2
(en)
|
2007-02-06 |
2012-05-08 |
Gordana Atallah |
PI 3-kinase inhibitors and methods of their use
|
|
JP2010518083A
(ja)
*
|
2007-02-12 |
2010-05-27 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ピペリジン誘導体
|
|
AU2008215948A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
|
JPWO2008111441A1
(ja)
|
2007-03-05 |
2010-06-24 |
協和発酵キリン株式会社 |
医薬組成物
|
|
NZ579485A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
MX2009009590A
(es)
*
|
2007-03-09 |
2009-11-10 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de proteinas cinasas.
|
|
EP2134709A1
(en)
|
2007-03-09 |
2009-12-23 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines useful as inhibitors of protein kinases
|
|
NZ580343A
(en)
|
2007-04-13 |
2012-03-30 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
|
US20100204246A1
(en)
*
|
2007-04-18 |
2010-08-12 |
Astrazeneca Ab |
5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
|
|
CA2688584A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
CA2694381A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
JP5389785B2
(ja)
*
|
2007-05-02 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤として有用なチアゾールおよびピラゾール
|
|
UA99459C2
(en)
*
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
NZ581259A
(en)
|
2007-05-09 |
2012-07-27 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
AU2008257044A1
(en)
*
|
2007-05-24 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
AU2008262291A1
(en)
*
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
|
WO2008156580A1
(en)
*
|
2007-06-13 |
2008-12-24 |
Merck & Co., Inc. |
Triazole derivatives for treating alzheimer's disease and related conditions
|
|
CN101687840A
(zh)
|
2007-06-25 |
2010-03-31 |
霍夫曼-拉罗奇有限公司 |
作为激酶抑制剂的苯并咪唑酰胺基衍生物
|
|
CN101801955B
(zh)
|
2007-07-05 |
2013-05-08 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
KR20150091196A
(ko)
*
|
2007-07-05 |
2015-08-07 |
어레이 바이오파마 인크. |
Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
|
|
KR20100038108A
(ko)
|
2007-07-25 |
2010-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
트리아진 키나제 억제제
|
|
AU2008282156B2
(en)
*
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
|
RU2010125220A
(ru)
*
|
2007-11-20 |
2011-12-27 |
Мерк Шарп Энд Домэ Корп. (Us) |
Ненуклеозидные ингибиторы обратной транскриптазы
|
|
AU2008333845C1
(en)
|
2007-12-07 |
2014-01-16 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
|
SI2639224T1
(sl)
*
|
2007-12-07 |
2016-12-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
|
|
JP2011032169A
(ja)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
４−アミノピリミジン誘導体および該化合物を含有する医薬組成物
|
|
WO2009078999A1
(en)
|
2007-12-17 |
2009-06-25 |
Janssen Pharmaceutica N.V. |
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
|
|
WO2009089462A1
(en)
*
|
2008-01-09 |
2009-07-16 |
Array Biopharma Inc. |
5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
|
|
TW200940542A
(en)
|
2008-01-09 |
2009-10-01 |
Array Biopharma Inc |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
MY152271A
(en)
|
2008-02-21 |
2014-09-15 |
Merck Sharp & Dohme |
Novel compounds that are erk inhibitors
|
|
CN102245573B
(zh)
|
2008-02-28 |
2013-11-20 |
沃泰克斯药物股份有限公司 |
作为cftr调节剂的杂芳基衍生物
|
|
WO2009145814A2
(en)
*
|
2008-03-10 |
2009-12-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidines and pyridines useful as inhibitors of protein kinases
|
|
CL2009000904A1
(es)
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
|
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
|
CN102105150B
(zh)
|
2008-05-21 |
2014-03-12 |
阿里亚德医药股份有限公司 |
用作激酶抑制剂的磷衍生物
|
|
KR20110017445A
(ko)
*
|
2008-06-11 |
2011-02-21 |
아스트라제네카 아베 |
암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
|
|
CN102118969B
(zh)
|
2008-06-12 |
2017-03-08 |
詹森药业有限公司 |
组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
|
|
WO2010002998A1
(en)
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
|
|
AU2009267161B2
(en)
*
|
2008-07-03 |
2014-11-06 |
Merck Patent Gmbh |
Naphthyridininones as Aurora kinase inhibitors
|
|
CA2729045A1
(en)
*
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
US20110251172A1
(en)
*
|
2008-08-13 |
2011-10-13 |
Rivkin Alexey A |
Purine derivatives for treatment of alzheimer's disease
|
|
CN102215816A
(zh)
*
|
2008-09-03 |
2011-10-12 |
沃泰克斯药物股份有限公司 |
共晶和包含所述共晶的药物制剂
|
|
CN104230901A
(zh)
*
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
WO2010038060A1
(en)
*
|
2008-09-30 |
2010-04-08 |
Astrazeneca Ab |
Heterocyclic jak kinase inhibitors
|
|
US20110257208A1
(en)
*
|
2008-11-19 |
2011-10-20 |
Matthew Duncton |
Compounds useful as faah modulators and uses thereof
|
|
KR101048448B1
(ko)
|
2008-11-21 |
2011-07-11 |
한국화학연구원 |
신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
|
|
ME02337B
(me)
|
2009-02-05 |
2016-06-20 |
Takeda Pharmaceuticals Co |
Jedinjenja piridazinona
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
MY159327A
(en)
*
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
EP2406236A4
(en)
*
|
2009-03-09 |
2013-07-24 |
Surface Logix Inc |
INHIBITORS OF RHO KINASE
|
|
JP2012521425A
(ja)
*
|
2009-03-23 |
2012-09-13 |
Ｍｓｄ株式会社 |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
EP2411011A4
(en)
*
|
2009-03-24 |
2012-08-15 |
Msd Kk |
NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION
|
|
US8263632B2
(en)
*
|
2009-03-24 |
2012-09-11 |
Vertex Pharmaceuticals Incoporated |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
|
WO2010144338A1
(en)
*
|
2009-06-08 |
2010-12-16 |
Abraxis Bioscience, Llc |
Triazine derivatives and their therapeutical applications
|
|
BRPI1011527A2
(pt)
*
|
2009-06-09 |
2016-07-26 |
California Capital Equity Llc |
derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
|
|
CN102573480B
(zh)
*
|
2009-06-09 |
2015-06-10 |
加利福尼亚资本权益有限责任公司 |
三嗪衍生物及其治疗应用
|
|
US20100331305A1
(en)
*
|
2009-06-24 |
2010-12-30 |
Genentech, Inc. |
Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
|
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β－類澱粉生成之化合物
|
|
US20110053916A1
(en)
|
2009-08-14 |
2011-03-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine compounds as tuberculosis inhibitors
|
|
CN102020657A
(zh)
*
|
2009-09-11 |
2011-04-20 |
上海艾力斯医药科技有限公司 |
稠合杂芳基衍生物、制备方法及其应用
|
|
MX2012005225A
(es)
|
2009-11-12 |
2012-07-25 |
Hoffmann La Roche |
Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
|
|
CN102711766B
(zh)
|
2009-11-12 |
2014-06-04 |
霍夫曼-拉罗奇有限公司 |
N-9-取代的嘌呤化合物、组合物和使用方法
|
|
BR112012020273A8
(pt)
|
2010-02-11 |
2017-12-26 |
Univ Vanderbilt |
compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
|
|
LT3150198T
(lt)
|
2010-04-07 |
2021-12-10 |
Vertex Pharmaceuticals Incorporated |
3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
MX2012014158A
(es)
|
2010-06-04 |
2013-02-07 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
|
|
US20110319409A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Cox Christopher D |
7-aza-quinazoline pde10 inhibitors
|
|
US8633207B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
CN103119035B
(zh)
|
2010-09-27 |
2015-09-30 |
雅培股份有限两合公司 |
杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
|
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
PH12013500880A1
(en)
|
2010-11-10 |
2013-07-01 |
Hoffmann La Roche |
Pyrazole aminopyrimidine derivatives as lrrk2 modulators
|
|
JP5937102B2
(ja)
|
2010-12-14 |
2016-06-22 |
エレクトロフォレティクス リミテッド |
カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
|
|
AU2011346567A1
(en)
|
2010-12-21 |
2013-07-25 |
Novartis Ag |
Bi-heteroaryl compounds as Vps34 inhibitors
|
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
US9481670B2
(en)
*
|
2011-01-25 |
2016-11-01 |
Sphaera Pharma Pte. Ltd. |
Triazine compounds
|
|
AU2012230229A1
(en)
|
2011-03-24 |
2013-10-10 |
Noviga Research Ab |
Novel pyrimidine derivatives
|
|
WO2012135759A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and abiraterone, and methods of use
|
|
CN103841976A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
US8846656B2
(en)
|
2011-07-22 |
2014-09-30 |
Novartis Ag |
Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
|
|
RU2014109897A
(ru)
|
2011-08-25 |
2015-09-27 |
Ф.Хоффманн-Ля Рош Аг |
Ингибиторы серин/треонин киназы рак1
|
|
HRP20190281T1
(hr)
|
2011-09-14 |
2019-05-31 |
Samumed, Llc |
Indazol-3-karboksamidi i njihova uporaba kao inhibitora signalizacijskog puta wnt/b-katenin
|
|
AU2012311184A1
(en)
|
2011-09-22 |
2014-03-06 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
|
JP6026544B2
(ja)
|
2011-09-27 |
2016-11-16 |
ノバルティス アーゲー |
変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
|
|
RU2014129740A
(ru)
|
2011-12-22 |
2016-02-10 |
Ф.Хоффманн-Ля Рош Аг |
Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
US8916555B2
(en)
*
|
2012-03-16 |
2014-12-23 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
US9932317B2
(en)
*
|
2012-03-19 |
2018-04-03 |
Imperial Innovations Limited |
Quinazoline compounds and their use in therapy
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
SMT201800608T1
(it)
|
2012-04-24 |
2019-01-11 |
Vertex Pharma |
Inibitori di dna-pk
|
|
KR102091895B1
(ko)
*
|
2012-05-03 |
2020-04-14 |
제넨테크, 인크. |
파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
|
|
JP6218808B2
(ja)
*
|
2012-05-03 |
2017-10-25 |
ジェネンテック， インコーポレイテッド |
Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
|
|
SG11201408679XA
(en)
|
2012-06-26 |
2015-01-29 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
|
EP2900666B1
(en)
|
2012-09-28 |
2020-11-04 |
Cancer Research Technology Limited |
Azaquinazoline inhibitors of atypical protein kinase c
|
|
JO3470B1
(ar)
|
2012-10-08 |
2020-07-05 |
Merck Sharp & Dohme |
مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
|
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
BR112015011456A2
(pt)
*
|
2012-11-20 |
2017-07-11 |
Genentech Inc |
compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
|
|
KR20220143164A
(ko)
|
2012-11-21 |
2022-10-24 |
피티씨 테라퓨틱스, 인크. |
치환된 리버스 피리미딘 ｂｍｉ-1 저해제
|
|
EP2943198B1
(en)
|
2013-01-08 |
2019-07-17 |
Samumed, LLC |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
|
CN103012428A
(zh)
|
2013-01-08 |
2013-04-03 |
中国药科大学 |
4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
|
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Ｆｌａｐ調節劑
|
|
WO2014121055A2
(en)
*
|
2013-02-04 |
2014-08-07 |
Janssen Pharmaceutica Nv |
Flap modulators
|
|
EP2769722A1
(en)
*
|
2013-02-22 |
2014-08-27 |
Ruprecht-Karls-Universität Heidelberg |
Compounds for use in inhibiting HIV capsid assembly
|
|
JO3377B1
(ar)
*
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
AU2014244555B2
(en)
|
2013-03-12 |
2018-06-28 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
GEP201706699B
(en)
|
2013-03-14 |
2017-07-10 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
KR20160104612A
(ko)
|
2013-07-26 |
2016-09-05 |
업데이트 파마 인코포레이트 |
비산트렌의 치료 효과 개선용 조성물
|
|
MX370588B
(es)
|
2013-08-30 |
2019-12-16 |
Ptc Therapeutics Inc |
Inhibidores de la bmi-1 de pirimidina sustituida.
|
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
|
ME02991B
(me)
|
2013-10-03 |
2018-10-20 |
Kura Oncology Inc |
Ekr inhibitori i postupci primene
|
|
US10125144B2
(en)
*
|
2013-10-07 |
2018-11-13 |
Kadmon Corporation, Llc |
Rho kinase inhibitors
|
|
HUE041877T2
(hu)
|
2013-10-17 |
2019-06-28 |
Vertex Pharma |
(S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
|
|
BR112016010403A2
(pt)
|
2013-11-12 |
2017-08-08 |
Vertex Pharma |
Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
|
|
WO2015076801A1
(en)
*
|
2013-11-21 |
2015-05-28 |
Ptc Therapeutics, Inc. |
Substituted triazine bmi-1 inhibitors
|
|
WO2015076800A1
(en)
*
|
2013-11-21 |
2015-05-28 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
|
CN104672250B
(zh)
*
|
2013-11-29 |
2017-11-07 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
LT3089971T
(lt)
|
2014-01-01 |
2020-10-12 |
Medivation Technologies Llc |
Junginiai ir panaudojimo būdai
|
|
WO2015112739A1
(en)
*
|
2014-01-22 |
2015-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds and method for treating parp1-deficient cancers
|
|
CN104926795B
(zh)
*
|
2014-03-17 |
2017-11-10 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
TWI675836B
(zh)
|
2014-03-25 |
2019-11-01 |
美商伊格尼塔公司 |
非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
|
|
CA2945263A1
(en)
|
2014-04-09 |
2015-10-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
CA2968130C
(en)
|
2014-11-18 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Process of conducting high throughput testing high performance liquid chromatography
|
|
TWI704151B
(zh)
*
|
2014-12-22 |
2020-09-11 |
美商美國禮來大藥廠 |
Ｅｒｋ抑制劑
|
|
US9879029B2
(en)
*
|
2014-12-22 |
2018-01-30 |
Eli Lilly And Company |
ERK inhibitors
|
|
US10227343B2
(en)
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
EP3070084A1
(en)
*
|
2015-03-18 |
2016-09-21 |
Rottapharm Biotech S.r.l. |
New fyn kinase inhibitors
|
|
US10752612B2
(en)
|
2015-04-17 |
2020-08-25 |
Ludwig Institute For Cancer Research Ltd |
PLK4 inhibitors
|
|
US10118904B2
(en)
|
2015-06-05 |
2018-11-06 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of Demyelinating Diseases
|
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
WO2017024015A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
KR20180080262A
(ko)
|
2015-11-06 |
2018-07-11 |
사뮤메드, 엘엘씨 |
골관절염의 치료
|
|
GB201604647D0
(en)
*
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
ES2933109T3
(es)
|
2016-06-01 |
2023-02-02 |
Biosplice Therapeutics Inc |
Proceso para preparar N-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida
|
|
US11110108B2
(en)
|
2016-09-27 |
2021-09-07 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
|
|
CN110709082A
(zh)
|
2016-10-21 |
2020-01-17 |
萨穆梅德有限公司 |
吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途
|
|
EP3534888B1
(en)
*
|
2016-11-01 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
|
|
KR102558716B1
(ko)
|
2016-11-07 |
2023-07-21 |
사뮤메드, 엘엘씨 |
단일-투여량, 즉시-사용가능한 주사용 제제
|
|
IT201700047189A1
(it)
*
|
2017-05-02 |
2018-11-02 |
Fondazione St Italiano Tecnologia |
Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
|
|
AR112027A1
(es)
*
|
2017-06-15 |
2019-09-11 |
Biocryst Pharm Inc |
Inhibidores de alk 2 quinasa que contienen imidazol
|
|
CA3063616A1
(en)
|
2017-06-30 |
2019-12-06 |
Beijing Tide Pharmaceutical Co., Ltd. |
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
|
|
WO2019000683A1
(zh)
|
2017-06-30 |
2019-01-03 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
|
CN110573501B
(zh)
*
|
2017-06-30 |
2023-09-29 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
|
CN109384774B
(zh)
*
|
2017-08-11 |
2023-02-17 |
中国科学院上海药物研究所 |
一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
|
|
GEP20227344B
(en)
|
2017-10-27 |
2022-01-25 |
Theravance Biopharma R&D Ip Llc |
Pyrimidine compound as jak kinase inhibitor
|
|
GB201801226D0
(en)
*
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
|
US12030857B2
(en)
*
|
2018-06-25 |
2024-07-09 |
Kadmon Corporation, Llc |
Glucose uptake inhibitors
|
|
WO2020055544A2
(en)
|
2018-08-17 |
2020-03-19 |
Ptc Therapeutics, Inc. |
Method for treating pancreatic cancer
|
|
AU2019323714A1
(en)
|
2018-08-24 |
2021-03-25 |
Jaguahr Therapeutics Pte Ltd |
Tetrahydropyridopyrimidine derivatives as AhR modulators
|
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
WO2020045941A1
(ko)
*
|
2018-08-27 |
2020-03-05 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
GEP20237519B
(en)
*
|
2018-12-27 |
2023-07-10 |
Servier Lab |
Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
|
|
KR20210111787A
(ko)
*
|
2019-01-03 |
2021-09-13 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질
|
|
AU2020218366A1
(en)
|
2019-02-08 |
2021-09-16 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and Wnt agonists for treating ear disorders
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
JP2022527744A
(ja)
|
2019-03-28 |
2022-06-06 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
JP2022528083A
(ja)
|
2019-03-29 |
2022-06-08 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
ピロロ複素環式誘導体、この誘導体のための調製方法及び医学におけるこの誘導体の用途
|
|
CN109826608A
(zh)
*
|
2019-04-08 |
2019-05-31 |
中国科学院地质与地球物理研究所 |
一种分段压裂装置
|
|
KR20220012248A
(ko)
*
|
2019-04-22 |
2022-02-03 |
베타 파머수티컬 컴퍼니 리미티드 |
퀴나졸린 화합물 및 이의 의약품에서의 응용
|
|
TW202106681A
(zh)
|
2019-04-24 |
2021-02-16 |
美商施萬生物製藥研發Ｉｐ有限責任公司 |
用於治療皮膚疾病之嘧啶jak抑制劑
|
|
TW202106682A
(zh)
|
2019-04-24 |
2021-02-16 |
美商施萬生物製藥研發Ｉｐ有限責任公司 |
作為jak激酶抑制劑之酯類及碳酸酯類嘧啶化合物
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
JP2022534224A
(ja)
|
2019-05-24 |
2022-07-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
置換縮合二環式誘導体、その調製方法、および医薬におけるその適用
|
|
MA56047A
(fr)
*
|
2019-05-29 |
2022-04-06 |
Ifm Due Inc |
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
|
|
BR112022002698A2
(pt)
|
2019-08-14 |
2022-07-19 |
Incyte Corp |
Compostos de imidazolil pirimidinilamina como inibidores de cdk2
|
|
US20220289692A1
(en)
*
|
2019-09-06 |
2022-09-15 |
Inflazome Limited |
Nlrp3 inhibitors
|
|
EP4041399A1
(en)
*
|
2019-10-02 |
2022-08-17 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
AU2020364007A1
(en)
|
2019-10-11 |
2022-04-28 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3167339A1
(en)
|
2020-01-13 |
2021-07-22 |
Verge Analytics, Inc. |
Substituted pyrazolo-pyrimidines and uses thereof
|
|
CN115244048A
(zh)
*
|
2020-02-26 |
2022-10-25 |
捷豹治疗有限公司 |
可用于调节AhR信号传导的吡啶并嘧啶衍生物
|
|
CA3176957A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Dong-A St Co., Ltd. |
Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
|
|
KR20230028798A
(ko)
|
2020-06-25 |
2023-03-02 |
톨레모 테라퓨틱스 아게 |
암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
|
|
SI4182308T1
(sl)
*
|
2020-07-15 |
2025-04-30 |
Chiesi Farmaceutici S.P.A. |
Piridazinil amino derivati kot zaviralci alk5
|
|
WO2022032484A1
(zh)
*
|
2020-08-11 |
2022-02-17 |
北京诺诚健华医药科技有限公司 |
哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
|
|
CN114149410B
(zh)
*
|
2020-09-07 |
2025-02-25 |
四川科伦博泰生物医药股份有限公司 |
吡啶并环类化合物及其制备方法和用途
|
|
JP2023543080A
(ja)
|
2020-09-29 |
2023-10-12 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
ピロロ複素環系誘導体の結晶及びその製造方法
|
|
WO2022107919A1
(ko)
*
|
2020-11-19 |
2022-05-27 |
주식회사 보로노이 |
N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
UY39832A
(es)
|
2021-06-28 |
2023-01-31 |
Blueprint Medicines Corp |
Inhibidores de cdk2
|
|
MX2024003399A
(es)
|
2021-09-21 |
2024-04-05 |
Chiesi Farm Spa |
Derivados de piridazinil-amino como inhibidores del receptor del factor de crecimiento transformante beta tipo i (alk5).
|
|
CN116023380B
(zh)
*
|
2021-10-26 |
2024-01-23 |
沈阳药科大学 |
一类吡唑并嘧啶衍生物及制备方法和应用
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
EP4463448A1
(en)
|
2022-01-11 |
2024-11-20 |
Chiesi Farmaceutici S.p.A. |
Pyridazinyl amino derivatives as alk5 inhibitors
|
|
WO2024206628A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Nalo Therapeutics |
Modulators of myc family proto-oncogene protein
|